NO20026085L - Ny anvendelse av angiotensin II antagonister - Google Patents

Ny anvendelse av angiotensin II antagonister

Info

Publication number
NO20026085L
NO20026085L NO20026085A NO20026085A NO20026085L NO 20026085 L NO20026085 L NO 20026085L NO 20026085 A NO20026085 A NO 20026085A NO 20026085 A NO20026085 A NO 20026085A NO 20026085 L NO20026085 L NO 20026085L
Authority
NO
Norway
Prior art keywords
angiotensin
antagonists
vascular headache
new use
treatment
Prior art date
Application number
NO20026085A
Other languages
English (en)
Other versions
NO330300B1 (no
NO20026085D0 (no
Inventor
Harald Schrader
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20026085L publication Critical patent/NO20026085L/no
Publication of NO20026085D0 publication Critical patent/NO20026085D0/no
Publication of NO330300B1 publication Critical patent/NO330300B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Mattresses And Other Support Structures For Chairs And Beds (AREA)
NO20026085A 2000-06-22 2002-12-18 Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom NO330300B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002353A SE0002353D0 (sv) 2000-06-22 2000-06-22 New use
PCT/SE2001/001379 WO2001097807A1 (en) 2000-06-22 2001-06-15 New use of angiotensin ii antagonists

Publications (3)

Publication Number Publication Date
NO20026085L true NO20026085L (no) 2002-12-18
NO20026085D0 NO20026085D0 (no) 2002-12-18
NO330300B1 NO330300B1 (no) 2011-03-28

Family

ID=20280208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026085A NO330300B1 (no) 2000-06-22 2002-12-18 Anvendelse av angiotensin II-antagonister for fremstilling av medikamenter for behandling av sykdom

Country Status (21)

Country Link
US (1) US7872035B2 (no)
EP (2) EP1307192B1 (no)
JP (1) JP2003535897A (no)
KR (1) KR100692235B1 (no)
CN (2) CN1250218C (no)
AT (1) ATE318597T1 (no)
AU (2) AU2001274765B2 (no)
BR (1) BR0111900A (no)
CA (1) CA2411553A1 (no)
DE (1) DE60117541T2 (no)
DK (1) DK1307192T3 (no)
ES (1) ES2257416T3 (no)
HK (1) HK1053609A1 (no)
IL (2) IL153158A0 (no)
MX (1) MXPA02012574A (no)
NO (1) NO330300B1 (no)
NZ (1) NZ523048A (no)
PT (1) PT1307192E (no)
SE (1) SE0002353D0 (no)
WO (1) WO2001097807A1 (no)
ZA (1) ZA200209902B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1356815A4 (en) * 2001-01-29 2007-03-07 Takeda Pharmaceutical ANALGESIC AND ANTI-INFLAMMATORY DRUGS
US20050065094A1 (en) * 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
FR2892803B1 (fr) 2005-10-28 2008-04-04 Valeo Systemes Thermiques Boite collectrice pour echangeur de chaleur, notamment pour evaporateur de climatisation, echangeur comportant une telle boite
JP5468420B2 (ja) * 2010-03-04 2014-04-09 株式会社マキタ 手持ち式切断工具
WO2012135597A2 (en) 2011-03-30 2012-10-04 The Johns Hopkins University Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
KR20130074808A (ko) 2011-12-16 2013-07-05 한올바이오파마주식회사 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5241009A (en) 1990-05-07 1993-08-31 Kimberly-Clark Corporation Polymeric composition containing carboxy nueutralized with lithium or potassium
CA2041763A1 (en) * 1990-05-11 1991-11-12 Sheih-Shung T. Chen Microbial transformation process for antihypertensive products
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5214153A (en) * 1992-04-23 1993-05-25 Merck & Co., Inc. Actinoplanes transformation process anti-hypertensive compound and method of use thereas

Also Published As

Publication number Publication date
CN1250218C (zh) 2006-04-12
JP2003535897A (ja) 2003-12-02
AU7476501A (en) 2002-01-02
KR20030019444A (ko) 2003-03-06
WO2001097807A1 (en) 2001-12-27
EP1307192B1 (en) 2006-03-01
SE0002353D0 (sv) 2000-06-22
KR100692235B1 (ko) 2007-03-09
NO330300B1 (no) 2011-03-28
DE60117541D1 (de) 2006-04-27
NZ523048A (en) 2004-09-24
CN1846697A (zh) 2006-10-18
EP1656940A1 (en) 2006-05-17
AU2001274765B2 (en) 2005-08-18
ZA200209902B (en) 2004-03-05
BR0111900A (pt) 2003-05-13
ATE318597T1 (de) 2006-03-15
IL153158A0 (en) 2003-06-24
IL153158A (en) 2008-03-20
MXPA02012574A (es) 2003-04-10
CA2411553A1 (en) 2001-12-27
ES2257416T3 (es) 2006-08-01
PT1307192E (pt) 2006-06-30
DE60117541T2 (de) 2006-09-14
HK1053609A1 (en) 2003-10-31
DK1307192T3 (da) 2006-06-12
EP1307192A1 (en) 2003-05-07
CN1447693A (zh) 2003-10-08
US7872035B2 (en) 2011-01-18
US20040092563A1 (en) 2004-05-13
NO20026085D0 (no) 2002-12-18

Similar Documents

Publication Publication Date Title
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2004091514A3 (en) Cgrp receptor antagonists
WO2004092166A3 (en) Cgrp receptor antagonists
JO2371B1 (en) 4-phenyl-pyridine derivatives
WO2005000807A3 (en) Benzodiazepine cgrp receptor antagonists
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
WO2001087838A8 (en) Cyclohexane derivatives and their use as therapeutic agents
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
BR0211604A (pt) Inibidores de integrina para o tratamento de doenças do olho
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
DE69613457D1 (de) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansäure derivate als tachykinin rezeptor antagonisten
NO20026085L (no) Ny anvendelse av angiotensin II antagonister
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE60224723D1 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten
DE69717969D1 (de) Substituierte n-methyl-n-(4-(piperidin-1-yl)-2-arylbutyl)-benzamide zur behandlung von allergischen erkrankungen
EA200300850A1 (ru) Применение антагонистов рецептора gal3 при лечении депрессии и/или тревоги и соединения, полезные в таких способах
WO2002053099A3 (en) Methods and compositions for treating periodontal disease
EP1095655A3 (en) NK-1 receptor antagonists and eletriptan for the treatment of migraine

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees